
STATUS UPDATE:

- (A) APPOINTMENT OF RECEIVERS OVER CERTAIN SUBSIDIARIES OF THE COMPANY**
 - (B) ARBITRATION AND ENFORCEMENT PROCEEDINGS AGAINST DAVID LIN KAO KUN**
 - (C) UPDATES ON VARIOUS LITIGATION PROCEEDINGS IN THE PEOPLE'S REPUBLIC OF CHINA**
-

1. INTRODUCTION

- 1. Unless otherwise defined, capitalised terms herein shall have the same meaning as ascribed to them in:
 - (a) the announcements of OUE Lippo Healthcare Limited (the "**Company**") between 3 May 2016 to 29 April 2019, in relation to, *inter alia*, the appointment of receivers over certain subsidiaries of the Company¹; and
 - (b) the announcements of the Company between 13 December 2017 and 29 April 2019 in relation to the arbitration and enforcement proceedings against David Lin Kao Kun ("**David Lin**")²; and
 - (c) the announcements of the Company between 22 February 2017 to 29 April 2019 in relation to on-going litigation with Weixin Hospital Investment Management (Shanghai) Co. Ltd (卫心医院投资管理(上海)有限公司) ("**Weixin**")³.

¹ 1 Please refer to the Company's announcements dated 3 May 2016, 6 May 2016, 8 July 2016, 8 August 2016, 15 August 2016, 16 September 2016, 13 October 2016, 21 October 2016, 14 November 2016, 24 November 2016, 15 December 2016, 13 January 2017, 11 March 2017, 29 April 2017, 17 May 2017, 16 June 2017, 29 June 2017, 13 July 2017, 22 August 2017, 28 September 2017, 25 October 2017, 22 November 2017, 28 December 2017, 24 January 2018, 28 February 2018, 27 March 2018, 30 April 2018, 28 May 2018, 26 June 2018, 2 July 2018, 26 July 2018, 27 August 2018, 27 September 2018, 29 October 2018, 30 November 2018, 27 December 2018, 29 January 2019, 28 February 2019, 28 March 2019 and 29 April 2019.

² Please refer to the Company's announcements dated 13 December 2017, 11 January 2018, 17 January 2019, 29 January 2019, 28 February 2019, 28 March 2019, 12 April 2019 and 29 April 2019.

³ Please refer to the Company's announcements dated 22 February 2017, 20 December 2017, 6 August 2018, 23 August 2018, 30 November 2018, 5 December 2018, 27 December 2018, 29 January 2019, 28 February 2019, 28 March 2019 and 29 April 2019.

OUE Lippo Healthcare Limited

Company Registration No. 201304341E

(In receivership over charged shares in certain subsidiaries)

6 Shenton Way, #10-09A, OUE Downtown 2, Singapore 068809

T: +65 6578 9188 F: 64794647 www.ouelh.com

2. APPOINTMENT OF RECEIVERS OVER CERTAIN SUBSIDIARIES OF THE COMPANY

2.1. CA 119

As announced previously on 2 July 2018, the High Court declared in OS 380 that the Standby Facility and its related contracts and transactions have been avoided, and the Company owes no contractual liability or obligation thereunder to the Crest Entities. As announced previously on 26 July 2018, the Crest Entities filed an appeal, CA 119, against the High Court's decision in OS 380 on 26 July 2018.

CA 119 was heard on 14 May 2019 at 2.30 pm before the Court of Appeal. The Court of Appeal reserved its judgment.

2.2. High Court Suit No. 441 of 2016 and High Court Suit No. 856 of 2016

As announced previously on 29 October 2018, High Court Suit No. 441 of 2016 and High Court Suit No. 856 of 2016 were fixed for trial on 2 to 5, 9 to 12, 16 to 19 July 2019 and 23 to 26 July 2019 (20 days). On 15 May 2019, the Court re-fixed the trial dates to 2 to 5, 9 to 12, and 23 to 26 July 2019 (16 days). Suit No. 441 of 2016 relates to, amongst others, proceedings against Fan Kow Hin for breach of his duties owed to the Company and/or unlawful conspiracy with Andrew Aathar and/or the Crest Entities in relation to the Standby Facility. Suit No. 856 of 2016 relates to the Crest Entities' claim against the Company in respect of the Standby Facility.

2.3. Aathar's Interim Order

As announced previously on 28 February 2019, Andrew Aathar applied on 24 January 2019 for an interim order to stay all legal proceedings against him in order to make his proposal for his third attempted voluntary arrangement with the creditors by way of OSB 8, and the Court granted Andrew Aathar the interim order sought in OSB 8 on 26 February 2019.

A creditor's meeting was called on 29 May 2019 as directed by the Court to consider Aathar's third attempted voluntary arrangement, that the Nominee is to file his report on the creditor's meeting by 12 June 2019 and that Andrew Aathar's interim order is extended to 12 June 2019.

3. ARBITRATION AND ENFORCEMENT PROCEEDINGS AGAINST DAVID LIN

As announced previously on 12 April 2019, David Lin has filed an application to the Singapore High Court (the "**Application**") to set aside the Award obtained by the Company against David Lin in the arbitration proceedings. On 25 April 2019, parties attended a pre-trial conference. The Court directed that the substantive hearing for the Application will be held on 1 July 2019.

OUE Lippo Healthcare Limited

Company Registration No. 201304341E

(In receivership over charged shares in certain subsidiaries)

6 Shenton Way, #10-09A, OUE Downtown 2, Singapore 068809

T: +65 6578 9188 F: 64794647 www.ouelh.com

On 23 May 2019, parties attended a pre-trial conference before the Court. David Lin's lawyers requested for an extension of time to file his reply affidavits. The Court allowed David Lin's application and directed that the substantive hearing for the Application be rescheduled to 22 July 2019.

The Company has been advised that the Application is frivolous and will vigorously defend the Application and provide further updates on the matter.

4. VARIOUS LITIGATION PROCEEDINGS IN THE PEOPLE'S REPUBLIC OF CHINA

4.1 Proceedings commenced by Weixin

As announced previously on 23 August 2018, Weixin commenced legal proceedings against Wuxi Yilin Real Estate Development Co Ltd (无锡医霖置业发展有限公司) ("**Wuxi Yilin Real Estate**") and Wuxi New District Phoenix Hospital Co., Ltd (无锡新区凤凰医院有限责任公司) ("**Wuxi Co**"), to seek a declaration that the land transfer agreement between Wuxi Yilin Real Estate and Wuxi Co. dated 15 January 2015 is void, and an order for the return of the land from Wuxi Yilin Real Estate to Wuxi Co.

As previously announced on 28 February 2019, the Court accepted Wuxi Co.'s Application for Judicial Expertise to examine the authenticity of the land transfer agreement registered with the Wuxi Housing Bureau and the housing transfer agreement registered with the Wuxi Land Bureau at the Court Conference on 20 February 2019. The Judicial Expert confirmed that the seals on the documents were authentic.

A hearing was scheduled before the Wuxi Xinwu District Court of 17 May 2019 to go through the substantive trial steps. Parties are waiting for the judgment of first instance to be rendered by the Wuxi Xinwu District Court.

4.2 Proceedings commenced by Health Kind International (Shanghai) Limited (上海医霖医院投资管理咨询有限公司) (also referred to as "Healthkind Investment Management Consulting Co. Ltd. ") ("Health Kind Shanghai")

As announced previously on 5 December 2018 and 29 January 2019, Health Kind Shanghai, a subsidiary of the Company, commenced legal proceedings before the Shanghai No. 1 Intermediate Court against Mr David Lin and Weixin, seeking 100% of the shares in Wuxi Co. In these proceedings, Health Kind Shanghai contends that Mr David Lin breached his fiduciary duties in causing Health Kind Shanghai to enter into rescission agreements on 8 November 2013 to transfer away Health Kind Shanghai's shares in Wuxi Co to Shanghai Yilin Medical Management Consulting Co., Ltd (上海医霖医疗管理咨询有限公司) ("**Shanghai Yilin**"), and thereafter causing Shanghai Yilin to transfer the same shares to Weixin.

OUE Lippo Healthcare Limited

Company Registration No. 201304341E

(In receivership over charged shares in certain subsidiaries)

6 Shenton Way, #10-09A, OUE Downtown 2, Singapore 068809

T: +65 6578 9188 F: 64794647 www.ouelh.com

On 16 May 2019, parties attended an evidentiary hearing before the Shanghai No. 1 Intermediate Court. At the hearing, parties submitted and exchanged their evidence, and raised their objections to the evidence submitted by the other party. The substantive hearing has been fixed on 26 June 2019.

The Company will provide further updates on the status of the above matters through SGXNET in accordance with the requirements under the applicable Catalyst Rules.

By Order of the Board
OUE Lippo Healthcare Limited

Mr. Yet Kum Meng
Chief Executive Officer and Executive Director
31 May 2019

*This announcement has been prepared by the Company and its contents have been reviewed by the Company's sponsor, PrimePartners Corporate Finance Pte. Ltd. (the "**Sponsor**"), in accordance with Rules 226(2)(b) and 753(2) of the Singapore Exchange Securities Trading Limited (the "**SGX-ST**") Listing Manual Section B: Rules of Catalyst.*

This announcement has not been examined or approved by the SGX-ST. The SGX-ST assume no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Ms Gillian Goh, Director, Head of Continuing Sponsorship (Mailing address: 16 Collyer Quay, #10-00 Income at Raffles, Singapore 049318 and E-mail: sponsorship@ppcf.com.sg).

OUE Lippo Healthcare Limited
Company Registration No. 201304341E
(In receivership over charged shares in certain subsidiaries)
6 Shenton Way, #10-09A, OUE Downtown 2, Singapore 068809
T: +65 6578 9188 F: 64794647 www.ouelh.com